Mariana Monteiro

Prof. Mariana Monteiro

Instituto de Ciências Biomédicas Abel Salazar - Porto
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Brain Research
Verified
Journal Article
Closed access
CACaroline R. Abbott
Caroline R. Abbott
MMMariana Monteiro
Mariana Monteiro
CSCaroline J. Small
Caroline J. Small
ASArshia Sajedi
Arshia Sajedi
KSKirsty L. Smith
Kirsty L. Smith
SBStephen R. Bloom
Stephen R. Bloom

1 June 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MBMichael Bergman
Michael Bergman
MAMuhammad Abdul-Ghani
Muhammad Abdul-Ghani
RDRalph A. A. DeFronzo
Ralph A. A. DeFronzo
Manco MelaniaManco Melania
Manco Melania
GSGiorgio Sesti
Giorgio Sesti
MBMartin Buysschaert
Martin Buysschaert

10 March 2022 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PPPedro R. Pereira
Pedro R. Pereira
David CarragetaDavid Carrageta
David Carrageta
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
ARAnabela Rodrigues
Anabela Rodrigues
Marco AlvesMarco Alves
Marco Alves
MMMariana Monteiro
Mariana Monteiro

1 January 2020 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
RPR Pasquali
R Pasquali
FCF Casanueva
F Casanueva
MHM Haluzik
M Haluzik
LHL van Hulsteijn
L van Hulsteijn
SLS Ledoux
S Ledoux
ODO M Dekkers
O M Dekkers
Obesity is an emerging condition, with a prevalence of ~20%. Although the simple measurement of BMI is likely a simplistic approach to obesity, BMI is easily calculated, and there are currently no data showing that more sophisticated methods are more useful to guide the endocrine work-up in obesity. An increased BMI leads to a number of hormonal changes. Additionally, concomitant hormonal diseases can be present in obesity and have to be properly diagnosed – which in turn might be more difficult due to alterations caused by body fatness itself. The present European Society of Endocrinology Clinical Guideline on the Endocrine Work-up in Obesity acknowledges the increased prevalence of many endocrine conditions in obesity. It is recommended to test all patients with obesity for thyroid function, given the high prevalence of hypothyroidism in obesity. For hypercortisolism, male hypogonadism and female gonadal dysfunction, hormonal testing is only recommended if case of clinical suspicion of an underlying endocrine disorder. The guideline underlines that weight loss in obesity should be emphasized as key to restoration of hormonal imbalances and that treatment and that the effect of treating endocrine disorders on weight loss is only modest.

29 April 2019 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
David CarragetaDavid Carrageta
David Carrageta
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
Marco AlvesMarco Alves
Marco Alves
MMMariana Monteiro
Mariana Monteiro

2 January 2014 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MNMário Nora
Mário Nora
MGMarta Guimarães
Marta Guimarães
RARui Almeida
Rui Almeida
PMPaulo Martins
Paulo Martins
GGGil Gonçalves
Gil Gonçalves
MMMariana Monteiro
Mariana Monteiro
Background: Metabolic syndrome (MS) is a condition associated with obesity that identifies individuals with increased cardiovascular risk. Gastric bypass improves several MS components, such as glucose, lipid metabolism and hypertension. The aim of this study was to evaluate the effect of long-limb gastric bypass on the remission of MS criteria associated with morbid obesity. Methods: Obese patients who met the “harmonized” criteria for MS (n = 153) that underwent laparoscopic Roux-en-Y gastric bypass (LRYGB) with a long biliopancreatic limb were prospectively evaluated with regards to body weight, body mass index (BMI), percentage of excess BMI lost (% EBMIL), fasting glucose, blood pressure and lipid profile up to 36 months after surgery. Results: Before surgery, patients had a BMI of 44.3 ± 0.5 kg/m2; 66% were under anti-diabetic treatment; 78.4% were under anti-hypertensive treatment and 44.3% were under anti-dyslipidemic treatment. After a mean follow-up time of 2.4 ± 0.1 years, MS remission rates were 32.7% at 6 months, 69.7% at 12 months, 63.4% at 24 months, and 59.2% at 36 months; when only 32.9%, 43.4% and 15.8% of patients were still under anti-diabetic, anti-hypertensive and anti-dyslipidemic treatment, respectively. The %EBMIL and BMI were the parameters that showed the highest accuracy to predict the MS remission at all-time points after the surgery. Conclusions: Long limb gastric bypass in obese patients results in significant and sustained weight loss which predicts a high remission rate of MS and allows the discontinuation of drug therapy for several metabolic disturbances in most patients.